8-K current report · filed Nov 5, 2026

Alector, Inc. (ALEC) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1ALEC overview

Short answer

Alector, Inc. (ALEC) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Alector announced financial results for the quarter ended September 30, 2026.

Alector, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Alector announced financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed earnings release and financial performance data

Item EX-99.1 · Exhibit EX-99.1

  • Q3 collaboration revenue $162.9M versus $3.3M, largely one-time recognition of deferred GSK revenue after termination
  • Net income $124.6M, or $1.11 per share, versus $34.7M loss, masking underlying biotech operating performance
  • Genentech license delivers $100M upfront, up to $1.17B milestones and tiered royalties for AL050
  • $75.0M stock offering at $2.05 per share, 36.6M shares, strengthening funding but creating dilution
  • Cash $138.7M before license and offering proceeds, extending projected runway into the second half of 2029

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Alector, Inc. 8-K filings

Get the next ALEC 8-K as it lands

Follow ALEC for push alerts, or ask the research agent what this filing means.